As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...
Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...
Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...
The drug leads to depletion of these cells via phagocytosis, a process in which ... The Dren Bio drug is currently being evaluated in two Phase 1 studies, one in healthy volunteers and the other ...
DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...
Sanofi has announced that it will be broadening its immunology pipeline by acquiring Dren Bio’s phase 1 CD20-directed ...
Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...
Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...
Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...
It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with ... enter the clinical development phase with the ABX-01 lead candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback